Limits...
Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study).

Aguilar-Salinas CA, Assis-Luores-Vale A, Stockins B, Rengifo HM, Dondici Filho J, Afiune Neto A, Rabelo LM, Torres KP, Oliveira JE, Machado CA, Reyes E, Saavedra V, Florenzano F, Hernández MV, Hernandez Jiménez S, Ramírez E, Vazquez C, Salinas S, Hernández I, Medel O, Moreno R, Lugo P, Alvarado R, Mehta R, Gutierrez V, Gómez Pérez FJ - Cardiovasc Diabetol (2004)

Bottom Line: Non-HDL cholesterol was decreased by 19%.There were no significant complications resulting from treatment with ciprofibrate.A greater decrease in non-HDL cholesterol was found among cases with excess body weight.

View Article: PubMed Central - HTML - PubMed

Affiliation: Departamento de Endocrinología y Metabolismo, Instituto Nacional de la Nutrición, México City, Mexico. caguilarsalinas@yahoo.com

ABSTRACT

Background: Hypertriglyceridemia in combination with low HDL cholesterol levels is a risk factor for cardiovascular disease. Our objective was to evaluate the efficacy of ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response.

Methods: Multicenter, international, open-label study. Four hundred and thirty seven patients were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between 1.6-3.9 mM/l and HDL cholesterol < or = 1.05 mM/l for women and < or = 0.9 mM/l for men. The LDL cholesterol was below 4.2 mM/l. All patients received ciprofibrate 100 mg/d. Efficacy and safety parameters were assessed at baseline and at the end of the treatment. The primary efficacy parameter of the study was percentage change in triglycerides from baseline.

Results: After 4 months, plasma triglyceride concentrations were decreased by 44% (p < 0.001). HDL cholesterol concentrations were increased by 10% (p < 0.001). Non-HDL cholesterol was decreased by 19%. A greater HDL cholesterol response was observed in lean patients (body mass index < 25 kg/m2) compared to the rest of the population (8.2 vs 19.7%, p < 0.001). In contrast, cases with excess body weight had a larger decrease in non-HDL cholesterol levels (-20.8 vs -10.8%, p < 0.001). There were no significant complications resulting from treatment with ciprofibrate.

Conclusions: Ciprofibrate is efficacious for the correction of hypertriglyceridemia / low HDL cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body weight. The mechanism of action of ciprofibrate may be influenced by the pathophysiology of the disorder being treated.

No MeSH data available.


Related in: MedlinePlus

The percentage of change in the lipid parameters is different in cases with a body mass index above 25 kg/m2 compared to the response observed in lean individuals during treatment with ciprofibrate and diet.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC503398&req=5

Figure 1: The percentage of change in the lipid parameters is different in cases with a body mass index above 25 kg/m2 compared to the response observed in lean individuals during treatment with ciprofibrate and diet.

Mentions: The lipid response during treatment differed between cases with a body mass index above or below 25 kg/m2. As is shown in figure 1, the percentage change in HDL cholesterol was higher in lean subjects. In contrast, the non-HDL cholesterol concentration had a significantly greater reduction among subjects with excess body weight. Both differences remained significant even after adjusting for age and gender. The lipid profile did not differ between these groups during the initial visit.


Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study).

Aguilar-Salinas CA, Assis-Luores-Vale A, Stockins B, Rengifo HM, Dondici Filho J, Afiune Neto A, Rabelo LM, Torres KP, Oliveira JE, Machado CA, Reyes E, Saavedra V, Florenzano F, Hernández MV, Hernandez Jiménez S, Ramírez E, Vazquez C, Salinas S, Hernández I, Medel O, Moreno R, Lugo P, Alvarado R, Mehta R, Gutierrez V, Gómez Pérez FJ - Cardiovasc Diabetol (2004)

The percentage of change in the lipid parameters is different in cases with a body mass index above 25 kg/m2 compared to the response observed in lean individuals during treatment with ciprofibrate and diet.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC503398&req=5

Figure 1: The percentage of change in the lipid parameters is different in cases with a body mass index above 25 kg/m2 compared to the response observed in lean individuals during treatment with ciprofibrate and diet.
Mentions: The lipid response during treatment differed between cases with a body mass index above or below 25 kg/m2. As is shown in figure 1, the percentage change in HDL cholesterol was higher in lean subjects. In contrast, the non-HDL cholesterol concentration had a significantly greater reduction among subjects with excess body weight. Both differences remained significant even after adjusting for age and gender. The lipid profile did not differ between these groups during the initial visit.

Bottom Line: Non-HDL cholesterol was decreased by 19%.There were no significant complications resulting from treatment with ciprofibrate.A greater decrease in non-HDL cholesterol was found among cases with excess body weight.

View Article: PubMed Central - HTML - PubMed

Affiliation: Departamento de Endocrinología y Metabolismo, Instituto Nacional de la Nutrición, México City, Mexico. caguilarsalinas@yahoo.com

ABSTRACT

Background: Hypertriglyceridemia in combination with low HDL cholesterol levels is a risk factor for cardiovascular disease. Our objective was to evaluate the efficacy of ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response.

Methods: Multicenter, international, open-label study. Four hundred and thirty seven patients were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between 1.6-3.9 mM/l and HDL cholesterol < or = 1.05 mM/l for women and < or = 0.9 mM/l for men. The LDL cholesterol was below 4.2 mM/l. All patients received ciprofibrate 100 mg/d. Efficacy and safety parameters were assessed at baseline and at the end of the treatment. The primary efficacy parameter of the study was percentage change in triglycerides from baseline.

Results: After 4 months, plasma triglyceride concentrations were decreased by 44% (p < 0.001). HDL cholesterol concentrations were increased by 10% (p < 0.001). Non-HDL cholesterol was decreased by 19%. A greater HDL cholesterol response was observed in lean patients (body mass index < 25 kg/m2) compared to the rest of the population (8.2 vs 19.7%, p < 0.001). In contrast, cases with excess body weight had a larger decrease in non-HDL cholesterol levels (-20.8 vs -10.8%, p < 0.001). There were no significant complications resulting from treatment with ciprofibrate.

Conclusions: Ciprofibrate is efficacious for the correction of hypertriglyceridemia / low HDL cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body weight. The mechanism of action of ciprofibrate may be influenced by the pathophysiology of the disorder being treated.

No MeSH data available.


Related in: MedlinePlus